Zonova, the antimicrobial materials company pioneering next generation infection-resistant medical devices, today announced the successful completion of its £2.1 million seed funding round led by THENA Capital, following a first close by Angel Academe, and participation from The Conduit Impact Fund, Arāya Sie Fund, The S100 Club, Animal Health Angels and a series of strategic investors from the healthcare and medical technology sectors.
The funding will accelerate Zonova’s commercialisation strategy as it partners with global medical device manufacturers to embed its proprietary Z-ROS® antimicrobial technology into high-volume medical devices starting with vascular access devices (peripheral intravenous and central venous catheters), with a clear pathway into urology, women’s health, orthopaedics and adjacent device categories.
Founded by Dr Georgia Fleet and Carla Southworth, Zonova has developed a novel antimicrobial material platform that integrates directly into medical device polymers rather than relying on traditional surface coatings or antibiotic-based approaches. The technology is designed to prevent microbial colonisation and biofilm formation, key drivers of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR), two of the most urgent global challenges facing healthcare systems today.